Prima Biomed Ltd (PBMD) 0.85 $PBMD European Pat
Post# of 273323
Posted On: 09/03/2016 11:19:40 AM
Prima Biomed Ltd (PBMD) 0.85 $PBMD
European Patent Grants for IMP731 Antibody
Marketwire Canada - Wed Aug 24, 7:37PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Aug 24, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the European Patent Office.
PBMD: 0.85 (unch)
Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
Marketwire Canada - Wed Aug 10, 2:56AM CDT
SYDNEY, AUSTRALIA--(Marketwired - Aug 10, 2016) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company", has received notification from the Listing Qualifications Department of The NASDAQ Stock Market (the "Staff" indicating that, for the period from June 24, 2016 through August 5, 2016, the closing bid price of the Company's American Depositary Shares, or ADS, had not been maintained at the minimum required closing bid price of at least US$1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule".
PBMD: 0.85 (unch)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.85 (unch), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), CELG: 105.49 (-0.88)
Prima BioMed to Maintain NASDAQ Listing
Marketwired - Mon Jun 06, 8:25PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 20 May 2016 to 3 June 2016. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule" and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market.
PBMD: 0.85 (unch)
Prima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) Program
Marketwired - Thu May 12, 3:26AM CDT
SYDNEY, AUSTRALIA and SEATTLE, WA--(Marketwired - May 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.85 (unch)
Prima BioMed Limited (NASDAQ: PBMD) Analyst Coverage Initiated
ACCESSWIRE - Tue May 03, 7:05AM CDT
SYDNEY, AUSTRALIA / ACCESSWIRE / May 3, 2016 / Prima BioMed Limited (NASDAQ: PBMD) an Australia-based biotechnology company engaged in research, development and commercialization of licensed medical biotechnology, recently announced the granting of patent number 5908210 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the Japanese Patent Office. This patent relates to Prima's IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima's AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3rd of October 2028.
PBMD: 0.85 (unch)
Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 0.85 (unch), EBIO: 4.84 (-0.05), OCLS: 4.14 (+0.01)
Prima BioMed wins US patent for IMP731 Antibody
M2 - Thu Jan 28, 3:34AM CST
Biotechnology company Prima BioMed (ASX
RR) (NASDAQBMD) disclosed on Wednesday the receipt of the patent entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" from the US Patent and Trademark Office.
PBMD: 0.85 (unch)
US Patent Grants for IMP731 Antibody
Marketwired - Wed Jan 27, 5:00PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" announces the granting of patent number US 9,244,059 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the United States Patent and Trademark Office.
PBMD: 0.85 (unch)
Prima BioMed to start Phase I melanoma study of IMP321 across Australia
M2 - Wed Jan 27, 3:16AM CST
Immuno-oncology company Prima BioMed (ASXRR) (NASDAQBMD) announced on Tuesday that TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, will now commence in the Gallipoli Medical Research Foundation at the Greenslopes Private Hospital in Queensland, Austrlaia.
PBMD: 0.85 (unch)
Prima BioMed Initiates Phase I Melanoma Study in Australia
Marketwired - Tue Jan 26, 4:51PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, to be conducted in Australia.
PBMD: 0.85 (unch)
Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
Marketwired - Tue Dec 22, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.85 (unch)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Fri Dec 11, 8:51AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
EYES: 3.44 (+0.08), PBMD: 0.85 (unch), CGEN: 7.41 (+0.36), ONTY: 1.21 (+0.02)
Prima BioMed Progresses Japanese Collaboration
Marketwired - Fri Dec 11, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. In this collaboration, first announced in May 2015, Prima's IMP321 Antigen Presenting Cell activator (APC) is being combined with a therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University.
PBMD: 0.85 (unch)
Prima BioMed Unveils Phase I Combination Study of IMP321 + Checkpoint Inhibitor
Marketwired - Wed Nov 18, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.85 (unch)
Prima BioMed announces AUD2.0m from equity placement with an Australian Institution
M2 - Mon Nov 02, 4:19AM CST
Immuno-oncology company Prima BioMed (ASXRR) (NASDAQBMD) said on Friday that it has raised AUD2.0m in an equity placement with an Australian Institution.
PBMD: 0.85 (unch)
European Patent Grants for IMP731 Antibody
Marketwire Canada - Wed Aug 24, 7:37PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Aug 24, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the European Patent Office. PBMD: 0.85 (unch)
Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
Marketwire Canada - Wed Aug 10, 2:56AM CDT
SYDNEY, AUSTRALIA--(Marketwired - Aug 10, 2016) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"
, has received notification from the Listing Qualifications Department of The NASDAQ Stock Market (the "Staff" indicating that, for the period from June 24, 2016 through August 5, 2016, the closing bid price of the Company's American Depositary Shares, or ADS, had not been maintained at the minimum required closing bid price of at least US$1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule". PBMD: 0.85 (unch)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.85 (unch), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), CELG: 105.49 (-0.88)
Prima BioMed to Maintain NASDAQ Listing
Marketwired - Mon Jun 06, 8:25PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 20 May 2016 to 3 June 2016. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"
and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market. PBMD: 0.85 (unch)
Prima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) Program
Marketwired - Thu May 12, 3:26AM CDT
SYDNEY, AUSTRALIA and SEATTLE, WA--(Marketwired - May 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.85 (unch)
Prima BioMed Limited (NASDAQ: PBMD) Analyst Coverage Initiated
ACCESSWIRE - Tue May 03, 7:05AM CDT
SYDNEY, AUSTRALIA / ACCESSWIRE / May 3, 2016 / Prima BioMed Limited (NASDAQ: PBMD) an Australia-based biotechnology company engaged in research, development and commercialization of licensed medical biotechnology, recently announced the granting of patent number 5908210 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the Japanese Patent Office. This patent relates to Prima's IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima's AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3rd of October 2028.
PBMD: 0.85 (unch)
Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 0.85 (unch), EBIO: 4.84 (-0.05), OCLS: 4.14 (+0.01)
Prima BioMed wins US patent for IMP731 Antibody
M2 - Thu Jan 28, 3:34AM CST
Biotechnology company Prima BioMed (ASX
RR) (NASDAQBMD) disclosed on Wednesday the receipt of the patent entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" from the US Patent and Trademark Office. PBMD: 0.85 (unch)
US Patent Grants for IMP731 Antibody
Marketwired - Wed Jan 27, 5:00PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
announces the granting of patent number US 9,244,059 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the United States Patent and Trademark Office. PBMD: 0.85 (unch)
Prima BioMed to start Phase I melanoma study of IMP321 across Australia
M2 - Wed Jan 27, 3:16AM CST
Immuno-oncology company Prima BioMed (ASX
RR) (NASDAQBMD) announced on Tuesday that TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, will now commence in the Gallipoli Medical Research Foundation at the Greenslopes Private Hospital in Queensland, Austrlaia. PBMD: 0.85 (unch)
Prima BioMed Initiates Phase I Melanoma Study in Australia
Marketwired - Tue Jan 26, 4:51PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, to be conducted in Australia.
PBMD: 0.85 (unch)
Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
Marketwired - Tue Dec 22, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.85 (unch)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Fri Dec 11, 8:51AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
EYES: 3.44 (+0.08), PBMD: 0.85 (unch), CGEN: 7.41 (+0.36), ONTY: 1.21 (+0.02)
Prima BioMed Progresses Japanese Collaboration
Marketwired - Fri Dec 11, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. In this collaboration, first announced in May 2015, Prima's IMP321 Antigen Presenting Cell activator (APC) is being combined with a therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University.
PBMD: 0.85 (unch)
Prima BioMed Unveils Phase I Combination Study of IMP321 + Checkpoint Inhibitor
Marketwired - Wed Nov 18, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.85 (unch)
Prima BioMed announces AUD2.0m from equity placement with an Australian Institution
M2 - Mon Nov 02, 4:19AM CST
Immuno-oncology company Prima BioMed (ASX
RR) (NASDAQBMD) said on Friday that it has raised AUD2.0m in an equity placement with an Australian Institution. PBMD: 0.85 (unch)
(0)
(0)